3. Oliva MS, Schottman T, Gulati M. Turning the tide of corneal blindness. Indian
J Ophthalmol. 2012 ;60(5):423-7.
4. Gupta N, Vashist P, Tandon R, Gupta SK, Dwivedi S, Mani K. Prevalence of corneal diseases in the rural Indian population: the Corneal Opacity Rural Epidemiological (CORE) study. Br J Ophthalmol. 2015;99(2):147-52.
5. Wang H, Zhang Y, Li Z, Wang T, Liu P. Prevalence and causes of corneal blindness. Clin Exp Ophthalmol. 2014;42(3):249-53.
6. Tang Y, Wang X, Wang J, Huang W, Gao Y, Luo Y, Lu Y. Prevalence and Causes of
Visual Impairment in a Chinese Adult Population: The Taizhou Eye Study. Ophthalmology. 2015 ;122(7):1480-8
7. Farmer LD, Ng SK, Rudkin A, Craig J, Wangmo D, Tsang H, Southisombath K, Griffiths A, Muecke J. Causes of Severe Visual Impairment and Blindness: Comparative Data From Bhutanese and Laotian Schools for the Blind. Asia Pac J Ophthalmol (Phila). 2015;4(6):350-6.
8. Shrestha JB, Gnyawali S, Upadhyay MP. Causes of blindness and visual impairment among students in integrated schools for the blind in Nepal. Ophthalmic Epidemiol. 2012 ;19(6):401-6.
9. Vashist P, Gupta N, Tandon R, Gupta SK, Dwivedi S, Mani K. Population-based assessment of vision-related quality of life in corneal disease: results from the CORE study. Br J Ophthalmol. 2016 ;100(5):588-93.
11. Edelhauser HF. The balance between corneal transparency and edema: the Proctor Lecture. Invest Ophthalmol Vis Sci. 2006;47(5):1754-67.
12. Li Q, Fukuda K, Lu Y, Nakamura Y, Chikama T, Kumagai N, Nishida T. Enhancement
by neutrophils of collagen degradation by corneal fibroblasts. J Leukoc Biol.
2003 ;74(3):412-9.
13. Ljubimov AV, Saghizadeh M. Progress in corneal wound healing. Prog Retin Eye
Res. 2015 ;49:17-45. doi: 10.1016/j.preteyeres.2015.07.002.
14. Huxlin KR, Hindman HB, Jeon KI, Bühren J, MacRae S, DeMagistris M, Ciufo D,
Sime PJ, Phipps RP. Topical rosiglitazone is an effective anti-scarring agent in
the cornea. PLoS One. 2013 5;8(8):e70785.
15. Trattler W. et al.Cornea handbook ( 1st ed.) Thorofare;Slack incorporated;2010.
16. Kalkanci A, Ozdek S. Ocular fungal infections. Curr Eye Res. 2011;36(3):179-89.
17.Mannis M, Holland E. Cornea Volume 1.Elsevier;2017.
18. Gain P, Jullienne R, He Z, Aldossary M, Acquart S, Cognasse F, Thuret G.
Global Survey of Corneal Transplantation and Eye Banking. JAMA Ophthalmol. 2016
;134(2):167-73.
19. Gomaa A, Comyn O, Liu C. Keratoprostheses in clinical practice - a review.
Clin Exp Ophthalmol. 2010 ;38(2):211-24.
20. Alio JL, Abbouda A, Vega-Estrada A. An innovative intrastromal
keratoprosthesis surgery assisted by femtosecond laser. Eur J Ophthalmol. 2014
;24(4):490-3.
21. Alio JL, Abdelghany AA, Abu-Mustafa SK, Zein G. A new epidescemetic
keratoprosthesis: pilot investigation and proof of concept of a new alternative
solution for corneal blindness. Br J Ophthalmol. 2015;99(11):1483-7.
22. Banitt M. Evaluation and management of glaucoma after keratoprosthesis. Curr
Opin Ophthalmol. 2011 ;22(2):133-6.
23. Robert MC, Moussally K, Harissi-Dagher M. Review of endophthalmitis following
Boston keratoprosthesis type 1. Br J Ophthalmol. 2012 ;96(6):776-80.
24. Griffith M, Alarcon EI, Brunette I. Regenerative approaches for the cornea. J
Intern Med. 2016;280(3):276-86. doi: 10.1111/joim.12502.
25. Bobba S, Di Girolamo N. Contact Lenses: A Delivery Device for Stem Cells to
Treat Corneal Blindness. Optom Vis Sci. 2016 ;93(4):412-8.
26. Parekh M, Ferrari S, Sheridan C, Kaye S, Ahmad S. Concise Review: An Update on
the Culture of Human Corneal Endothelial Cells for Transplantation. Stem Cells
Transl Med. 2016 Feb;5(2):258-64.
27. Geneva: WHO Press;2009: World Health Assembly Document A62/7: Action plan for the prevention of avoidable blindness and visual impairment. 2009-2013;pp.7-17.
Visual Impairmient and blindness among patients with corneal pathologies
This mini review discusses the corneal blindness worldwide, its epidemiology, treatment and prevention modalities. It gives brief informayion about blinding corneal pathologies
3. Oliva MS, Schottman T, Gulati M. Turning the tide of corneal blindness. Indian
J Ophthalmol. 2012 ;60(5):423-7.
4. Gupta N, Vashist P, Tandon R, Gupta SK, Dwivedi S, Mani K. Prevalence of corneal diseases in the rural Indian population: the Corneal Opacity Rural Epidemiological (CORE) study. Br J Ophthalmol. 2015;99(2):147-52.
5. Wang H, Zhang Y, Li Z, Wang T, Liu P. Prevalence and causes of corneal blindness. Clin Exp Ophthalmol. 2014;42(3):249-53.
6. Tang Y, Wang X, Wang J, Huang W, Gao Y, Luo Y, Lu Y. Prevalence and Causes of
Visual Impairment in a Chinese Adult Population: The Taizhou Eye Study. Ophthalmology. 2015 ;122(7):1480-8
7. Farmer LD, Ng SK, Rudkin A, Craig J, Wangmo D, Tsang H, Southisombath K, Griffiths A, Muecke J. Causes of Severe Visual Impairment and Blindness: Comparative Data From Bhutanese and Laotian Schools for the Blind. Asia Pac J Ophthalmol (Phila). 2015;4(6):350-6.
8. Shrestha JB, Gnyawali S, Upadhyay MP. Causes of blindness and visual impairment among students in integrated schools for the blind in Nepal. Ophthalmic Epidemiol. 2012 ;19(6):401-6.
9. Vashist P, Gupta N, Tandon R, Gupta SK, Dwivedi S, Mani K. Population-based assessment of vision-related quality of life in corneal disease: results from the CORE study. Br J Ophthalmol. 2016 ;100(5):588-93.
11. Edelhauser HF. The balance between corneal transparency and edema: the Proctor Lecture. Invest Ophthalmol Vis Sci. 2006;47(5):1754-67.
12. Li Q, Fukuda K, Lu Y, Nakamura Y, Chikama T, Kumagai N, Nishida T. Enhancement
by neutrophils of collagen degradation by corneal fibroblasts. J Leukoc Biol.
2003 ;74(3):412-9.
13. Ljubimov AV, Saghizadeh M. Progress in corneal wound healing. Prog Retin Eye
Res. 2015 ;49:17-45. doi: 10.1016/j.preteyeres.2015.07.002.
14. Huxlin KR, Hindman HB, Jeon KI, Bühren J, MacRae S, DeMagistris M, Ciufo D,
Sime PJ, Phipps RP. Topical rosiglitazone is an effective anti-scarring agent in
the cornea. PLoS One. 2013 5;8(8):e70785.
15. Trattler W. et al.Cornea handbook ( 1st ed.) Thorofare;Slack incorporated;2010.
16. Kalkanci A, Ozdek S. Ocular fungal infections. Curr Eye Res. 2011;36(3):179-89.
17.Mannis M, Holland E. Cornea Volume 1.Elsevier;2017.
18. Gain P, Jullienne R, He Z, Aldossary M, Acquart S, Cognasse F, Thuret G.
Global Survey of Corneal Transplantation and Eye Banking. JAMA Ophthalmol. 2016
;134(2):167-73.
19. Gomaa A, Comyn O, Liu C. Keratoprostheses in clinical practice - a review.
Clin Exp Ophthalmol. 2010 ;38(2):211-24.
20. Alio JL, Abbouda A, Vega-Estrada A. An innovative intrastromal
keratoprosthesis surgery assisted by femtosecond laser. Eur J Ophthalmol. 2014
;24(4):490-3.
21. Alio JL, Abdelghany AA, Abu-Mustafa SK, Zein G. A new epidescemetic
keratoprosthesis: pilot investigation and proof of concept of a new alternative
solution for corneal blindness. Br J Ophthalmol. 2015;99(11):1483-7.
22. Banitt M. Evaluation and management of glaucoma after keratoprosthesis. Curr
Opin Ophthalmol. 2011 ;22(2):133-6.
23. Robert MC, Moussally K, Harissi-Dagher M. Review of endophthalmitis following
Boston keratoprosthesis type 1. Br J Ophthalmol. 2012 ;96(6):776-80.
24. Griffith M, Alarcon EI, Brunette I. Regenerative approaches for the cornea. J
Intern Med. 2016;280(3):276-86. doi: 10.1111/joim.12502.
25. Bobba S, Di Girolamo N. Contact Lenses: A Delivery Device for Stem Cells to
Treat Corneal Blindness. Optom Vis Sci. 2016 ;93(4):412-8.
26. Parekh M, Ferrari S, Sheridan C, Kaye S, Ahmad S. Concise Review: An Update on
the Culture of Human Corneal Endothelial Cells for Transplantation. Stem Cells
Transl Med. 2016 Feb;5(2):258-64.
27. Geneva: WHO Press;2009: World Health Assembly Document A62/7: Action plan for the prevention of avoidable blindness and visual impairment. 2009-2013;pp.7-17.
Akova, B., & Kıvanç, S. A. (2019). Visual Impairmient and blindness among patients with corneal pathologies. Clinical and Experimental Ocular Trauma and Infection, 1(2), 100-103.
AMA
Akova B, Kıvanç SA. Visual Impairmient and blindness among patients with corneal pathologies. CEOTI. Ağustos 2019;1(2):100-103.
Chicago
Akova, Berna, ve Sertaç Argun Kıvanç. “Visual Impairmient and Blindness Among Patients With Corneal Pathologies”. Clinical and Experimental Ocular Trauma and Infection 1, sy. 2 (Ağustos 2019): 100-103.
EndNote
Akova B, Kıvanç SA (01 Ağustos 2019) Visual Impairmient and blindness among patients with corneal pathologies. Clinical and Experimental Ocular Trauma and Infection 1 2 100–103.
IEEE
B. Akova ve S. A. Kıvanç, “Visual Impairmient and blindness among patients with corneal pathologies”, CEOTI, c. 1, sy. 2, ss. 100–103, 2019.
ISNAD
Akova, Berna - Kıvanç, Sertaç Argun. “Visual Impairmient and Blindness Among Patients With Corneal Pathologies”. Clinical and Experimental Ocular Trauma and Infection 1/2 (Ağustos 2019), 100-103.
JAMA
Akova B, Kıvanç SA. Visual Impairmient and blindness among patients with corneal pathologies. CEOTI. 2019;1:100–103.
MLA
Akova, Berna ve Sertaç Argun Kıvanç. “Visual Impairmient and Blindness Among Patients With Corneal Pathologies”. Clinical and Experimental Ocular Trauma and Infection, c. 1, sy. 2, 2019, ss. 100-3.
Vancouver
Akova B, Kıvanç SA. Visual Impairmient and blindness among patients with corneal pathologies. CEOTI. 2019;1(2):100-3.